
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6833623/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Regeneration linked miRNA modify tumor phenotype and can enforce multi-lineage growth arrest in vivo. Scientific Reports, 2021, 11, 10538.	3.3	2
2	Induced dendritic cells co-expressing GM-CSF/IFN-α/tWT1 priming T and B cells and automated manufacturing to boost GvL. Molecular Therapy - Methods and Clinical Development, 2021, 21, 621-641.	4.1	5
3	Gene-edited healthy donor CAR T cells show superior anti-tumour activity compared to CAR T cells derived from patients with lymphoma in an in vivo model of high-grade lymphoma. Leukemia, 2021, 35, 3581-3584.	7.2	13
4	Chimeric antigen receptorâ€modified human regulatory T cells that constitutively express ILâ€10 maintain their phenotype and are potently suppressive. European Journal of Immunology, 2021, 51, 2522-2530.	2.9	15
5	Durable Responses and Low Toxicity After Fast Off-Rate CD19 Chimeric Antigen Receptor-T Therapy in Adults With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia. Journal of Clinical Oncology, 2021, 39, 3352-3363.	1.6	59
6	Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies. Lancet, The, 2020, 396, 1885-1894.	13.7	206
7	Engineered Tumor-Derived Extracellular Vesicles: Potentials in Cancer Immunotherapy. Frontiers in Immunology, 2020, 11, 221.	4.8	76
8	Serum MicroRNA Signatures in Recovery From Acute and Chronic Liver Injury and Selection for Liver Transplantation, 2020, 26, 811-822.	2.4	17
9	Generation and Clinical Application of Gene-Modified Autologous Epidermal Sheets in Netherton Syndrome: Lessons Learned from a Phase 1 Trial. Human Gene Therapy, 2019, 30, 1067-1078.	2.7	27
10	Immunosenescence and Its Hallmarks: How to Oppose Aging Strategically? A Review of Potential Options for Therapeutic Intervention. Frontiers in Immunology, 2019, 10, 2247.	4.8	463
11	Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR. Nature Medicine, 2019, 25, 1408-1414.	30.7	394
12	Pre-clinical Safety and Efficacy of Lentiviral Vector-Mediated ExÂVivo Stem Cell Gene Therapy for the Treatment of Mucopolysaccharidosis IIIA. Molecular Therapy - Methods and Clinical Development, 2019, 13, 399-413.	4.1	37
13	Antitumor Reactive T-Cell Responses Are Enhanced In Vivo by DAMP Prothymosin Alpha and Its C-Terminal Decapeptide. Cancers, 2019, 11, 1764.	3.7	10
14	Safety and early efficacy outcomes for lentiviral fibroblast gene therapy in recessive dystrophic epidermolysis bullosa. JCI Insight, 2019, 4, .	5.0	56
15	Triggering of Toll-like Receptors in Old Individuals. Relevance for Vaccination. Current Pharmaceutical Design, 2019, 25, 4163-4167.	1.9	8
16	Lentiviral Vector Purification Using Genetically Encoded Biotin Mimic in Packaging Cell. Molecular Therapy - Methods and Clinical Development, 2018, 11, 155-165.	4.1	17
17	IL-15/IL-15Rα/CD80-expressing AML cell vaccines eradicate minimal residual disease in leukemic mice. Blood Advances, 2018, 2, 3177-3192.	5.2	10
18	A phase I trial of T4 CAR T-cell immunotherapy in head and neck squamous cancer (HNSCC) Journal of Clinical Oncology, 2018, 36, 3046-3046.	1.6	34

FARZIN FARZANEH

#	Article	IF	CITATIONS
19	Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells. Science Translational Medicine, 2017, 9, .	12.4	707
20	Transactivator protein: An alternative for delivery of recombinant proteins for safer reprogramming of induced Pluripotent Stem Cell. Virus Research, 2017, 235, 106-114.	2.2	19
21	Cancer Immunotherapy: Whence and Whither. Molecular Cancer Research, 2017, 15, 635-650.	3.4	30
22	Retroviral insertional mutagenesis implicates E3 ubiquitin ligase RNF168 in the control of cell proliferation and survival. Bioscience Reports, 2017, 37, .	2.4	5
23	The Use of PARP Inhibitors in Cancer Therapy: Use as Adjuvant with Chemotherapy or Radiotherapy, Use as a Single Agent in Susceptible Patients, and Techniques Used to Identify Susceptible Patients. Methods in Molecular Biology, 2017, 1608, 343-370.	0.9	7
24	Deep phenotyping of Tregs identifies an immune signature for idiopathic aplastic anemia and predicts response to treatment. Blood, 2016, 128, 1193-1205.	1.4	117
25	Transient Expression of Green Fluorescent Protein in Integrase-Defective Lentiviral Vector-Transduced 293T Cell Line. Methods in Molecular Biology, 2016, 1448, 159-173.	0.9	5
26	Lentiviral Engineered Fibroblasts Expressing Codon-Optimized COL7A1 Restore Anchoring Fibrils in RDEB. Journal of Investigative Dermatology, 2016, 136, 284-292.	0.7	42
27	Donor Lymphocyte Infusions Correct Deficiency of Naive T Cells and Improve T-Cell Competence after Allogeneic Haematopoietic Stem Cell Transplantation with Lymphocyte Depletion. Blood, 2016, 128, 2233-2233.	1.4	0
28	A Novel Second Generation CD19 CAR for Therapy of High Risk/Relapsed Paediatric CD19+ Acute Lymphoblastic Leukaemia and Other Haematological Malignancies: Preliminary Results from the Carpall Study. Blood, 2016, 128, 4026-4026.	1.4	1
29	The combined molecular adjuvant CASAC enhances the CD8+ T cell response to a tumor-associated self-antigen in aged, immunosenescent mice. Immunity and Ageing, 2015, 12, 6.	4.2	8
30	Active dendritic cell immunotherapy for glioblastoma: Current status and challenges. British Journal of Neurosurgery, 2015, 29, 197-205.	0.8	21
31	Glyco-engineered anti-EGFR mAb elicits ADCC by NK cells from colorectal cancer patients irrespective of chemotherapy. British Journal of Cancer, 2014, 110, 1221-1227.	6.4	25
32	Optimised concentration and purification of retroviruses using membrane chromatography. Journal of Chromatography A, 2014, 1340, 24-32.	3.7	34
33	Open-label, multicentre expansion cohort to evaluate imgatuzumab in pre-treated patients with KRAS-mutant advanced colorectal carcinoma. European Journal of Cancer, 2014, 50, 496-505.	2.8	26
34	Phase I Study Protocol for <i>Ex Vivo</i> Lentiviral Gene Therapy for the Inherited Skin Disease, Netherton Syndrome. Human Gene Therapy Clinical Development, 2013, 24, 182-190.	3.1	37
35	Apoptosis Suppression by Candidate Oncogene PLAC8 is Reversed in Other Cell Types. Current Cancer Drug Targets, 2013, 13, 80-91.	1.6	49
36	The effects of 5-azacytidine on the function and number of regulatory T cells and T-effectors in myelodysplastic syndrome. Haematologica, 2013, 98, 1196-1205.	3.5	91

#	Article	IF	CITATIONS
37	Microsatellite instability induced mutations in DNA repair genes CtIP and MRE11 confer hypersensitivity to poly (ADP-ribose) polymerase inhibitors in myeloid malignancies. Haematologica, 2013, 98, 1397-1406.	3.5	58
38	Production and First-in-Man Use of T Cells Engineered to Express a HSVTK-CD34 Sort-Suicide Gene. PLoS ONE, 2013, 8, e77106.	2.5	32
39	Long-term efficacy and pharmacodynamic parameter analysis in pretreated KRAS-mutant metastatic colorectal carcinoma (mCRC) patients treated with RG7160 (GA201), an antibody-dependent cellular cytotoxicity (ADCC)-enhanced monoclonal anti-EGFR antibody Journal of Clinical Oncology, 2013, 31, 379-379.	1.6	0
40	Inhibition Of PI3K Classia Kinases Using GDC0941 Overcomes Protection Of Multiple Myeloma Cells In The Bone Marrow Microenvironment. Blood, 2013, 122, 3169-3169.	1.4	16
41	Human Gyrovirus Apoptin shows a similar subcellular distribution pattern and apoptosis induction as the chicken anaemia virus derived VP3/Apoptin. Cell Death and Disease, 2012, 3, e296-e296.	6.3	29
42	Functional characterization of CD4+ T cells in aplastic anemia. Blood, 2012, 119, 2033-2043.	1.4	140
43	A functional assay for microRNA target identification and validation. Nucleic Acids Research, 2012, 40, e75-e75.	14.5	27
44	Lentivirus capture directly from cell culture with Q-functionalised microcapillary film chromatography. Journal of Chromatography A, 2012, 1251, 236-239.	3.7	8
45	Are snoRNAs and snoRNA host genes new players in cancer?. Nature Reviews Cancer, 2012, 12, 84-88.	28.4	304
46	A critical role for non-coding RNA <i>GAS5</i> in growth arrest and rapamycin inhibition in human T-lymphocytes. Biochemical Society Transactions, 2011, 39, 482-486.	3.4	96
47	The Use of PARP Inhibitors in Cancer Therapy: Use as Adjuvant with Chemotherapy or Radiotherapy; Use as a Single Agent in Susceptible Patients; Techniques Used to Identify Susceptible Patients. Methods in Molecular Biology, 2011, 780, 239-266.	0.9	5
48	Functional Characterization of CD4+ T-Cells in Aplastic Anemia (AA). Blood, 2011, 118, 1340-1340.	1.4	1
49	5-Azacytidine Specifically Depletes Regulatory T Cells (Tregs) in Myelodysplastic Syndrome (MDS) Patients. Blood, 2011, 118, 787-787.	1.4	2
50	CD80-IL2 Expressing Myeloma Cells for Immune Gene Therapy of Multiple Myeloma. Blood, 2011, 118, 4718-4718.	1.4	0
51	Lytic activity against primary AML cells is stimulated in vitro by an autologous whole cell vaccine expressing IL-2 and CD80. Cancer Immunology, Immunotherapy, 2010, 59, 379-388.	4.2	13
52	Affinity recovery of lentivirus by diaminopelargonic acid mediated desthiobiotin labelling. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2010, 878, 1939-1945.	2.3	15
53	Crucial Roles for Protein Kinase C Isoforms in Tumor-Specific Killing by Apoptin. Cancer Research, 2010, 70, 7242-7252.	0.9	29
54	Inhibition of Human T-Cell Proliferation by Mammalian Target of Rapamycin (mTOR) Antagonists Requires Noncoding RNA Growth-Arrest-Specific Transcript 5 (GAS5). Molecular Pharmacology, 2010, 78, 19-28.	2.3	121

FARZIN FARZANEH

#	Article	IF	CITATIONS
55	Growth arrest in human T-cells is controlled by the non-coding RNA growth-arrest-specific transcript 5 ( <i>GAS5</i> ). Journal of Cell Science, 2010, 123, 1181-1181.	2.0	5
56	Coniothalamin-induced oxidative stress, DNA damage and apoptosis via caspase-2 independent and Bcl-2 independent pathways in Jurkat T-cells. Toxicology Letters, 2010, 193, 108-114.	0.8	53
57	Generation of functional CD8+ T Cells by human dendritic cells expressing glypican-3 epitopes. Journal of Experimental and Clinical Cancer Research, 2010, 29, 48.	8.6	18
58	Evaluation of anti-inflammatory and antinociceptive activities of <i>Murraya exotica</i> . Pharmaceutical Biology, 2010, 48, 1344-1353.	2.9	39
59	A Functional Assay for MicroRNA Target Identification and Validation. Blood, 2010, 116, 3874-3874.	1.4	0
60	Dysfunctional Tregs with Absence of Cytokine-Secreting CD4+ T-Cell Subsets and Marked Expansion of Th1 Cells Is a Hallmark of Idiopathic Aplastic Anaemia (AA). Blood, 2010, 116, 2233-2233.	1.4	0
61	The Structure and Pharmacological Functions of Coumarins and Their Derivatives. Current Medicinal Chemistry, 2009, 16, 4236-4260.	2.4	228
62	Inhibitors of poly ADP-ribose polymerase (PARP) induce apoptosis of myeloid leukemic cells: potential for therapy of myeloid leukemia and myelodysplastic syndromes. Haematologica, 2009, 94, 638-646.	3.5	78
63	Inhibition of major histocompatibility complex Class I antigen presentation by hepatitis C virus core protein in myeloid dendritic cells. Virology, 2009, 389, 1-7.	2.4	11
64	Human CD80/IL2 lentivirus transduced acute myeloid leukaemia cells enhance cytolytic activity in vitro in spite of an increase in regulatory CD4+ T cells in a subset of cultures. Cancer Immunology, Immunotherapy, 2009, 58, 1679-1690.	4.2	6
65	ILâ€17â€producing CD4 <sup>+</sup> T cells, proâ€inflammatory cytokines and apoptosis are increased in low risk myelodysplastic syndrome. British Journal of Haematology, 2009, 145, 64-72.	2.5	169
66	Human CD80/IL2 lentivirusâ€ŧransduced acute myeloid leukaemia (AML) cells promote natural killer (NK) cell activation and cytolytic activity: implications for a phase I clinical study. British Journal of Haematology, 2009, 145, 749-760.	2.5	20
67	GAS5, a non-protein-coding RNA, controls apoptosis and is downregulated in breast cancer. Oncogene, 2009, 28, 195-208.	5.9	736
68	PML involvement in the p73-mediated E1A-induced suppression of EGFR and induction of apoptosis in head and neck cancers. Oncogene, 2009, 28, 3499-3512.	5.9	11
69	Immobilized metal affinity chromatography of histidine-tagged lentiviral vectors using monolithic adsorbents. Journal of Chromatography A, 2009, 1216, 2705-2711.	3.7	47
70	Delivery of Therapeutic Proteins as Secretable TAT Fusion Products. Molecular Therapy, 2009, 17, 334-342.	8.2	53
71	RACK-1 overexpression protects against goniothalamin-induced cell death. Toxicology Letters, 2009, 191, 118-122.	0.8	16
72	Preparation and Characterization of Prostate Cell Lines for Functional Cloning Studies to Identify Regulators of Apoptosis. Journal of Andrology, 2009, 30, 248-258.	2.0	5

#	Article	IF	CITATIONS
73	Generation in vivo of peptide-specific cytotoxic T cells and presence of regulatory T cells during vaccination with hTERT (class I and II) peptide-pulsed DCs. Journal of Translational Medicine, 2009, 7, 18.	4.4	23
74	Anti-tumor immunity in a model of acute myeloid leukemia. Leukemia and Lymphoma, 2009, 50, 447-454.	1.3	5
75	Simple Magnetic Cell Patterning Using Streptavidin Paramagnetic Particles. Experimental Biology and Medicine, 2009, 234, 332-341.	2.4	17
76	Adenoâ€associated virusâ€mediated expression of kallistatin suppresses local and remote hepatocellular carcinomas. Journal of Gene Medicine, 2008, 10, 508-517.	2.8	31
77	Transcriptional regulation of the hepatocyte growth factor gene by pyrrolidine dithiocarbamate. FEBS Letters, 2008, 582, 1859-1864.	2.8	0
78	Harnessing the tumour-derived cytokine, CSF-1, to co-stimulate T-cell growth and activation. Molecular Immunology, 2008, 45, 1276-1287.	2.2	37
79	WFDC1/ps20 Is a Novel Innate Immunomodulatory Signature Protein of Human Immunodeficiency Virus (HIV)-Permissive CD4 <sup>+</sup> CD45RO <sup>+</sup> Memory T Cells That Promotes Infection by Upregulating CD54 Integrin Expression and Is Elevated in HIV Type 1 Infection. Journal of Virology, 2008, 82, 471-486.	3.4	24
80	Combined Triggering of Dendritic Cell Receptors Results in Synergistic Activation and Potent Cytotoxic Immunity. Journal of Immunology, 2008, 181, 3422-3431.	0.8	51
81	Growth arrest in human T-cells is controlled by the non-coding RNA growth-arrest-specific transcript 5 ( <i>GAS5</i> ). Journal of Cell Science, 2008, 121, 939-946.	2.0	213
82	Chromosomal instability syndromes are sensitive to poly ADP-ribose polymerase inhibitors. Haematologica, 2008, 93, 1886-1889.	3.5	16
83	Poly ADP Ribose Polymerase (PARP) Inhibitors Induce Apoptosis Alone or Synergistically with Histone Deacetylase Inhibitors in Primary Acute Myeloid Leukemic Patient Cells. Blood, 2008, 112, 2974-2974.	1.4	1
84	RFUSIN2 - a Clinical Grade Lentiviral Vector Co-Expressing CD80/IL-2 Manufactured Under GMP for a Phase I Clinical Trial Study of Immune Gene Therapy for Poor Prognosis Acute Myeloid Leukaemia. Blood, 2008, 112, 4630-4630.	1.4	0
85	In-Vitro Culture of Human CD80/IL2 Lentivirus Transduced Acute Myeloid Leukemia Cells (AML) Promote NK Cell Activation and Cytolytic Activity. Blood, 2008, 112, 2969-2969.	1.4	2
86	Increased Number of IL-17 Producing CD4+ T Cells in Low Risk Myelodysplastic Syndrome (MDS). Blood, 2008, 112, 637-637.	1.4	0
87	Recent Advances and Current Challenges in Tumor Immunology and Immunotherapy. Molecular Therapy, 2007, 15, 1065-1071.	8.2	29
88	CD4+CD25high Foxp3+ regulatory T cells in myelodysplastic syndrome (MDS). Blood, 2007, 110, 847-850.	1.4	234
89	p400 function is required for the adenovirus E1A-mediated suppression of EGFR and tumour cell killing. Oncogene, 2007, 26, 6863-6874.	5.9	21
90	Induction of tumor-specific T-cell responses by vaccination with tumor lysate-loaded dendritic cells in colorectal cancer patients with carcinoembryonic-antigen positive tumors. Cancer Immunology, Immunotherapy, 2007, 56, 2003-2016.	4.2	44

#	Article	IF	CITATIONS
91	Semi-allogeneic dendritic cells can induce antigen-specific T-cell activation, which is not enhanced by concurrent alloreactivity. Cancer Immunology, Immunotherapy, 2007, 56, 1861-1873.	4.2	22
92	Inhibition of angiogenesis and HCT-116 xenograft tumor growth in mice by kallistatin. World Journal of Gastroenterology, 2007, 13, 4615.	3.3	22
93	Hepatocyte Growth Factor Expression in Bone Marrow Microenvironment Is Critical for Progression of MGUS to Myeloma Blood, 2007, 110, 4766-4766.	1.4	0
94	CD4+CD25high Foxp3+ Regulatory T-Cells Are Correlated with Different Risk Factors in Myelodysplastic Syndrome (MDS) Blood, 2007, 110, 2445-2445.	1.4	0
95	Metabolic Biotinylation of Lentiviral Pseudotypes for Scalable Paramagnetic Microparticle-Dependent Manipulation. Molecular Therapy, 2006, 13, 814-822.	8.2	47
96	Characterization and Clinical Application of Human CD34 <sup>+</sup> Stem/Progenitor Cell Populations Mobilized into the Blood by Granulocyte Colonyâ€Stimulating Factor. Stem Cells, 2006, 24, 1822-1830.	3.2	267
97	Development of a whole cell vaccine for acute myeloid leukaemia. Cancer Immunology, Immunotherapy, 2006, 55, 68-75.	4.2	19
98	An immune edited tumour versus a tumour edited immune system: prospects for immune therapy of acute myeloid leukaemia. Cancer Immunology, Immunotherapy, 2006, 55, 1017-1024.	4.2	31
99	The strange case of TGN1412. Cancer Immunology, Immunotherapy, 2006, 56, 129-134.	4.2	18
100	Cytoglobin Overexpression Protects against Damage-Induced Fibrosis. Molecular Therapy, 2006, 13, 1093-1100.	8.2	90
101	Inhibition of Poly ADP Ribose Polymerase (PARP) Activity Exerts Cytotoxic Effects on Chromosomal Instability Syndrome and Leukaemic Cell Lines: Potential for Anti-Leukaemia Therapy Blood, 2006, 108, 2647-2647.	1.4	1
102	TAT-Apoptin Mediated Induction of Apoptosis in Leukaemic Cells Blood, 2006, 108, 1900-1900.	1.4	0
103	Expansion of Polyclonal CD4+CD25high Foxp3+ Regulatory T-Cells in High Risk Myelodysplastic Syndromes (MDS) Blood, 2006, 108, 2641-2641.	1.4	0
104	Isolation of genes controlling apoptosis through their effects on cell survival. Gene Therapy and Molecular Biology, 2006, 10, 255-262.	1.3	18
105	Affinity recovery of Moloney Murine Leukaemia Virus. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2005, 820, 111-119.	2.3	17
106	Influence of Interleukin-4 on the Phenotype and Function of Bone Marrow-Derived Murine Dendritic Cells Generated Under Serum-Free Conditions. Scandinavian Journal of Immunology, 2005, 61, 251-259.	2.7	33
107	Functional expression cloning reveals a central role for the receptor for activated protein kinase C 1 (RACK1) in T cell apoptosis. Journal of Leukocyte Biology, 2005, 78, 503-514.	3.3	33
108	Conjugation of Lentivirus to Paramagnetic Particles via Nonviral Proteins Allows Efficient Concentration and Infection of Primary Acute Myeloid Leukemia Cells. Journal of Virology, 2005, 79, 13190-13194.	3.4	38

#	Article	IF	CITATIONS
109	Overexpression of Soluble TRAIL Induces Apoptosis in Human Lung Adenocarcinoma and Inhibits Growth of Tumor Xenografts in Nude Mice. Cancer Research, 2005, 65, 1687-1692.	0.9	116
110	IL-2/B7.1 (CD80) Fusagene Transduction of AML Blasts by a Self-Inactivating Lentiviral Vector Stimulates T Cell Responses in Vitro: a Strategy to Generate Whole Cell Vaccines for AML. Molecular Therapy, 2005, 11, 120-131.	8.2	49
111	Single zinc-finger extension: enhancing transcriptional activity and specificity of three-zinc-finger proteins. Biological Chemistry, 2005, 386, 95-99.	2.5	3
112	TAT-apoptin is efficiently delivered and induces apoptosis in cancer cells. Oncogene, 2004, 23, 1153-1165.	5.9	124
113	Regulation of apoptosis by fau revealed by functional expression cloning and antisense expression. Oncogene, 2004, 23, 9419-9426.	5.9	30
114	The use of gene function to identify the rate-limiting steps controlling cell fate. Cancer Immunology, Immunotherapy, 2004, 53, 160-165.	4.2	14
115	Strategies for antigen choice and priming of dendritic cells influence the polarization and efficacy of antitumor T-cell responses in dendritic cell?based cancer vaccination. Cancer Immunology, Immunotherapy, 2004, 53, 963-77.	4.2	58
116	Growth factor displayed on the surface of retroviral particles without manipulation of envelope proteins is biologically active and can enhance transduction. Journal of Gene Medicine, 2004, 6, 1189-1196.	2.8	18
117	Distribution of fetal erythroblasts in maternal blood after chorionic villous sampling. BJOG: an International Journal of Obstetrics and Gynaecology, 2003, 110, 33-38.	2.3	7
118	Functional expression cloning reveals proapoptotic role for protein phosphatase 4. Cell Death and Differentiation, 2003, 10, 1016-1024.	11.2	39
119	E1A-mediated suppression of EGFR expression and induction of apoptosis in head and neck squamous carcinoma cell lines. Oncogene, 2003, 22, 1965-1977.	5.9	31
120	Distribution of fetal erythroblasts enriched from maternal blood in multifetal pregnancies. Human Reproduction, 2003, 18, 1933-1936.	0.9	4
121	Dendritic cell function in patients with hepatocellular carcinoma. Journal of Hepatology, 2002, 36, 78.	3.7	0
122	B7.1 and Cytokines. Advances in Experimental Medicine and Biology, 2002, , 381-390.	1.6	4
123	Eliciting cytotoxic T lymphocytes against acute myeloid leukemia-derived antigens: evaluation of dendritic cell-leukemia cell hybrids and other antigen-loading strategies for dendritic cell-based vaccination. Cancer Immunology, Immunotherapy, 2002, 51, 299-310.	4.2	126
124	An Iron-Regulated Ferric Reductase Associated with the Absorption of Dietary Iron. Science, 2001, 291, 1755-1759.	12.6	897
125	Protein transduction: a new tool for the study of cellular ageing and senescence. Mechanisms of Ageing and Development, 2001, 121, 113-121.	4.6	13
126	The Use of Intracellular Single-Chain Antibody Fragments to Specifically Inhibit Cytokine Secretion. International Archives of Allergy and Immunology, 2001, 124, 216-217.	2.1	1

#	Article	IF	CITATIONS
127	Selective Cleavage of BLM, the Bloom Syndrome Protein, during Apoptotic Cell Death. Journal of Biological Chemistry, 2001, 276, 12068-12075.	3.4	21
128	Local versus systemic interleukin-2: Tumor formation by wild-type and B7-1-positive murine melanoma cells. Cancer Gene Therapy, 2000, 7, 207-214.	4.6	9
129	Regulation of HGF/SF Gene Expression in MRC-5 Cells by N-Acetylcysteine. Biochemical and Biophysical Research Communications, 2000, 279, 108-115.	2.1	8
130	A Novel Duodenal Iron-Regulated Transporter, IREG1, Implicated in the Basolateral Transfer of Iron to the Circulation. Molecular Cell, 2000, 5, 299-309.	9.7	1,294
131	The Human and Mouse GATA-6 Genes Utilize Two Promoters and Two Initiation Codons. Journal of Biological Chemistry, 1999, 274, 38004-38016.	3.4	65
132	Investigation of maternal blood enriched for fetal cells: Role in screening and diagnosis of fetal trisomies. American Journal of Medical Genetics Part A, 1999, 85, 66-75.	2.4	48
133	Modulation of Fos-mediated AP-1 transcription by the promyelocytic leukemia protein. Oncogene, 1998, 16, 2843-2853.	5.9	49
134	Changes in antigen expression on differentiating HL60 cells treated with dimethylsulphoxide, all-trans retinoic acid, α1,25-dihydroxyvitamin D3 or 12-O-tetradecanoyl phorbol-13-acetate. Leukemia Research, 1998, 22, 537-547.	0.8	75
135	Gene therapy of cancer. Trends in Immunology, 1998, 19, 294-296.	7.5	19
136	Regulation of HGF gene expression by TGF-Î <sup>2</sup> 1. Journal of Hepatology, 1998, 28, 60.	3.7	1
137	Regulation of hepatocyte growth factor gene expression by N-acetylcysteine. Journal of Hepatology, 1998, 28, 85.	3.7	0
138	Thymidine Phosphorylase Activity and Prodrug Effects in a Three-Dimensional Model of Angiogenesis. American Journal of Pathology, 1998, 153, 1573-1578.	3.8	12
139	The Use of PCR for Differential Screening of cDNA Libraries. , 1997, 67, 405-418.		3
140	Irradiated NC Adenocarcinoma Cells Transduced with Both B7.1 and Interleukin-2 Induce CD4+-Mediated Rejection of Established Tumors. Human Gene Therapy, 1997, 8, 477-488.	2.7	33
141	Transcriptional Repression by the Promyelocytic Leukemia Protein, PML. Experimental Cell Research, 1997, 237, 371-382.	2.6	44
142	Plasma levels and hepatic mRNA expression of transforming growth factor-β1 in patients with fulminant hepatic failure. Journal of Hepatology, 1997, 27, 780-788.	3.7	45
143	Enhanced immune costimulatory activity of primary acute myeloid leukaemia blasts after retrovirus-mediated gene transfer of B7.1. Gene Therapy, 1997, 4, 691-699.	4.5	52
144	In vitro immune modulation by antibodies coupled to tumour cells. Gene Therapy, 1997, 4, 1350-1360.	4.5	14

FARZIN FARZANEH

#	Article	IF	CITATIONS
145	Molecular cloning of human GATA-6 DNA binding protein: high levels of expression in heart and gut. Biochimica Et Biophysica Acta Gene Regulatory Mechanisms, 1997, 1353, 98-102.	2.4	28
146	Regulation of Pancreatitis-Associated Protein (HIP/PAP) mRNA Levels in Mouse Pancreas and Small Intestine. Clinical Science, 1996, 91, 213-218.	4.3	19
147	Fetal hepatic alpha-fetoprotein mRNA expression in fetuses with trisomy 21 and 18 at 12–15 weeks gestation. Early Human Development, 1996, 44, 155-159.	1.8	10
148	The effect of combined expression of interleukin 2 and interleukin 4 on the tumorigenicity and treatment of B16F10 melanoma. British Journal of Cancer, 1996, 74, 6-15.	6.4	18
149	Molecular interactions during pregnancy. Molecular Human Reproduction, 1996, 2, 463-465.	2.8	10
150	Genomic variations in the hepatitis B core gene: A possible factor influencing response to interferon alfa treatment. Gastroenterology, 1995, 108, 505-514.	1.3	65
151	Association of ovarian Malignancy With Expression of Paltelet-Derived Endothelial Cell Growth Factor. Journal of the National Cancer Institute, 1994, 86, 1234-1238.	6.3	148
152	Whole chromosome 17 loss in ovarian cancer. Genes Chromosomes and Cancer, 1993, 8, 195-198.	2.8	34
153	Retinoid receptors and acute promyelocytic leukaemia. European Journal of Cancer, 1993, 29, 2046-2054.	2.8	3
154	Case against subclassification of type II autoimmune chronic active hepatitis. Lancet, The, 1993, 341, 60.	13.7	52
155	Sequencing of cDNA using anchored oligo dT primers. Nucleic Acids Research, 1993, 21, 3915-3916.	14.5	11
156	Analysis of hepatitis B virus (HBV) pre-core/core gene in relation to the response to alpha interferon (IFN): A study in U.S. Caucasians. Hepatology, 1993, 18, A113.	7.3	0
157	Alcohol dehydrogenase: A constituent of LSP and target of autoimmune reactions in liver disease. Hepatology, 1993, 18, A172.	7.3	1
158	Retroviral Vectors as Insertional Mutagens. , 1992, 8, 111-130.		0
159	(E6) Involvement of RAR-α in the RA inducible regulation of myeloid cell differentiation. Leukemia Research, 1991, 15, 11.	0.8	Ο
160	DMSO and retinoic acid induce HL-60 differentiation by different but converging pathways. Experimental Cell Research, 1990, 190, 137-140.	2.6	20
161	HL-R5 and HL-D4: Two differentiation resistant HL-60 variants. Leukemia Research, 1989, 13, 407-415.	0.8	3
162	c-erbB-2/c-erbA co-amplification indicative of lymph node metastasis, and c-myc amplification of high tumour grade, in human breast carcinoma. British Journal of Cancer, 1989, 60, 505-510.	6.4	66

#	Article	IF	CITATIONS
163	Protein kinase C mediates the hormonally regulated plasma membrane fusion of avian embryonic skeletal muscle. Experimental Cell Research, 1989, 181, 298-304.	2.6	11
164	Inhibition of ADP-Ribosyl Transferase Activity Blocks the Stable Integeration of Transfected DNA into the Mammalian Cell Genome. , 1989, , 189-193.		0
165	ADP-ribosylation is involved in the integration of foreign DNA into the mammalian cell genome. Nucleic Acids Research, 1988, 16, 11319-11326.	14.5	68
166	Transient formation of DNA strand breaks during the induced differentiation of a human promyelocytic leukaemic cell line, HL-60. Nucleic Acids Research, 1987, 15, 3493-3502.	14.5	45
167	DNA repair in human promyelocytic cell line, HL-60. Nucleic Acids Research, 1987, 15, 3503-3513.	14.5	18
168	The response of Trypanosoma brucei to DNA-damaging agents. Biochemical Society Transactions, 1986, 14, 105-106.	3.4	1
169	The response of cultured Trypanosmona brucei to DNA-damaging agents. Biochemical Society Transactions, 1986, 14, 486-487.	3.4	1
170	ADP-ribosyl transferase activity in Trypanosoma brucei. Molecular and Biochemical Parasitology, 1985, 14, 251-259.	1.1	19
171	ADP-Ribosyltransferase Activity in Trypanosoma brucei. Proceedings in Life Sciences, 1985, , 367-371.	0.5	4
172	Effect of 3-aminobenzamide on antigenic variation of Trypanosoma brucei. Biochemical Pharmacology, 1985, 34, 4151-4156.	4.4	19
173	The dynamic nature of DNA-strand breaks present in differentiating muscle cells and quiescent lymphocytes. FEBS Letters, 1985, 189, 62-66.	2.8	24
174	Studies on autoantibodies to poly (adenosine diphosphate-ribose) in SLE and other autoimmune diseases Annals of the Rheumatic Diseases, 1982, 41, 396-402.	0.9	29
175	DNA strand breaks and ADP-ribosyl transferase activation during cell differentiation. Nature, 1982, 300, 362-366.	27.8	353
176	The activity and properties of poly(adenosine diphosphate ribose) polymerase in vitro during the embryonic development of the South African clawed toad Xenopus laevis. Developmental Biology, 1979, 72, 254-265.	2.0	29
177	Poly(adenosine diphosphate ribose) synthesis by isolated nuclei of Xenopus, laevis embryos: Invitro elongation of invivo synthesized chains. Biochemical and Biophysical Research Communications, 1978, 84, 537-543.	2.1	20
178	The Activity of Poly(Adenosine Diphosphate Ribose) Polymerase during the Embryonic Development of the South African Clawed Toad Xenopus laevis. Biochemical Society Transactions, 1977, 5, 733-734.	3.4	7